We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Novozymes Enters Into an Exclusive Supplier Agreement to Supply Recombumin®

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Novozymes Enters Into an Exclusive Supplier Agreement to Supply Recombumin®"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novozymes Biopharma has announced that it has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, California. Novozymes will supply its recombinant human albumin, Recombumin®, for use in the development of a new GLP-1 analog in Phase 2 testing for Type 2 diabetes.

The use of Recombumin in the development of the product potentially significantly reduces dosing frequency, allowing patients to self-inject once per week instead of once or twice daily.

“This supply agreement is a great example of using Novozymes’ Recombumin as a vehicle for extending the half-life of peptides in drug delivery applications,” said Thomas Videbæk, Executive Vice President of Novozymes’ BioBusiness.

Videbæk continued, “Also the agreement for this new drug will potentially pave the way for the use of Recombumin in other peptide-based therapies.”

Recombumin is the only commercially available, animal-free recombinant human albumin approved for use in human therapeutics.

Manufactured to cGMP quality standards in large-scale facilities, the product is compliant with United States Pharmacopeia (USP) National Formulary (NF) standards and is supported by a strongly documented safety package and drug master file.

These features greatly improve regulatory approval processes for therapeutics, thus accelerating the time to market.

In addition, Recombumin offers a secure supply and batch-to-batch consistency, which reduces processing and testing times to drive product efficiencies for manufacturers.

Patrick Soon-Shiong, M.D., CEO at ConjuChem, said: “This exclusive agreement is an excellent partnership for Conjuchem. The Recombumin technology, and the strong commitment from Novozymes, will be key as we develop next generation treatment for a disease affecting more than 360 million people worldwide.”